Clinical Trials Directory

Trials / Completed

CompletedNCT01086423

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+Hib™) in Infants

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
985 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
60 Days – 90 Days
Healthy volunteers
Accepted

Summary

The purpose of the study is to evaluate the immunogenicity and reactogenicity of Infanrix-IPV/Hib™ vaccine when administered to healthy Chinese infants at 2, 3 and 4 or 3, 4 and 5 months of age.

Conditions

Interventions

TypeNameDescription
BIOLOGICALInfanrix-IPV/Hib™Intramuscular, three doses
BIOLOGICALInfanrix Hib™Intramuscular, three doses
BIOLOGICALPoliorix™Intramuscular, three doses

Timeline

Start date
2010-03-01
Primary completion
2010-11-19
Completion
2010-11-19
First posted
2010-03-15
Last updated
2018-06-06
Results posted
2017-04-10

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT01086423. Inclusion in this directory is not an endorsement.